Chisena S, Antonelli D, Bernasconi S, Zaroli A, Buizza C, Belloni M, Mandressi A
U.O. di Urologia, Busto Arsizio.
Arch Ital Urol Androl. 1996 Feb;68(1):51-4.
From June 1991 to June 1995 we treated 20 patients affected by T1 G3 TCC of the bladder, 18 men and 2 women, with a mean age of 65.1 years (46-71). In 11 patients the disease was monofocal, with diameter of the tumor under 3.5 cms; in 5 patients monofocal with diameter of the tumor over 3.5 cms; in 1 patient multifocal and in 3 patients complex (mono or multifocal associated with CIS). The 11 patients with monofocal disease under 3.5 cms were treated with TUR-B, the other 9 (all males) were submitted to radical cystectomy with OINB diversion as first choice treatment. The mean follow up (all patients) was 3.2 years (6 months-14 years). Out of the patients of the former group only 3 did not show any relapse, the other 8 showed multiple relapses or metachronous tumors: 5 were treated with TUR-B+BCG, 3 were cystectomized. The patients submitted to cystectomy as first choice treatment did not show any progression of the disease after a mean follow-up of 19.8 months.
1991年6月至1995年6月，我们治疗了20例膀胱T1 G3移行细胞癌患者，其中男性18例，女性2例，平均年龄65.1岁（46 - 71岁）。11例患者的疾病为单灶性，肿瘤直径小于3.5厘米；5例患者为单灶性，肿瘤直径大于3.5厘米；1例患者为多灶性，3例患者为复杂性（单灶或多灶合并原位癌）。11例肿瘤直径小于3.5厘米的单灶性疾病患者接受了经尿道膀胱肿瘤切除术（TUR - B）治疗，另外9例（均为男性）则首选根治性膀胱切除术并采用回肠原位新膀胱术（OINB）改道。平均随访时间（所有患者）为3.2年（6个月至14年）。前一组患者中只有3例未出现任何复发，其他8例出现多次复发或异时性肿瘤：5例接受了TUR - B +卡介苗（BCG）治疗，3例接受了膀胱切除术。作为首选治疗接受膀胱切除术的患者在平均随访19.8个月后未出现疾病进展。
